Clinical Research Directory
Browse clinical research sites, groups, and studies.
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
Sponsor: Emory University
Summary
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Official title: Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell Disease
Key Details
Gender
All
Age Range
7 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2015-05
Completion Date
2026-07
Last Updated
2025-07-11
Healthy Volunteers
No
Conditions
Interventions
Arginine
Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge. * Loading dose: 200 mg/kg once * Continuous IV: 300 mg/kg/24 hours
Arginine (Loading)
Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first.
Arginine (Continuous)
Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
Locations (2)
Children's Healthcare fo Atlanta at Hughes Spalding
Atlanta, Georgia, United States
Children's Healthcare of Atlanta at Arthur M. Blank Hospital
Atlanta, Georgia, United States